Side-by-side earnings comparison across financial stats, AI summaries, management guidance, risks, quotes, and accountability signals.
Emcure delivered a strong Q4 FY26 with revenue of ₹2,470 crore (+16.7% YoY) and EBITDA margin expansion of 130 bps to 19.7%, driven by robust international growth (+25.7%) and operating leverage.
Read Emcure Pharmaceuticals analysis →Metropolis Healthcare delivered a strong FY26 with group revenue of ₹1,646 crore (+23.6% YoY) and EBITDA margin of 24.4%.
Read Metropolis Healthcare analysis →Emcure delivered a strong Q4 FY26 with revenue of ₹2,470 crore (+16.7% YoY) and EBITDA margin expansion of 130 bps to 19.7%, driven by robust international growth (+25.7%) and operating leverage. Domestic business was soft (+5.2%) due to Zuventus restructuring, but management confirmed April is back on track. Adjusted PAT grew 36% YoY to ₹279 crore. Guidance for FY27: low-to-mid teen revenue growth and 75-100 bps margin expansion, assuming stable macro conditions. Key growth levers include semaglutide partnership (Pista), biosimilar launches (Vasumarelic, Lenacapavir), and ADC pipeline. Risk: sustained geopolitical disruption could raise raw material costs and freight, pressuring margins if not passed through.
Metropolis Healthcare delivered a strong FY26 with group revenue of ₹1,646 crore (+23.6% YoY) and EBITDA margin of 24.4%. Organic revenue grew 13.7% YoY, exceeding the 12-13% guidance, driven by patient volume growth of 7.5% and realization improvement. Organic EBITDA margin expanded 140 bps to 25.9%, aided by lab platform upgrades, vendor consolidation, and operating leverage. The core diagnostics acquisition achieved high single-digit EBITDA margin within four quarters, on track for 20%+ in three years. Management guided for 14-15% organic revenue growth and 27-28% group EBITDA margin over the next three years, supported by network productivity gains, specialty mix improvement, and digital channel expansion. Key risks include competitive intensity in tier-1 cities and potential integration challenges from future M&A.
Strong growth across Europe (+35.8%), Canada (+28.6%), and emerging markets (+15.5%).
Revenue per medical representative improved from ₹5.4 lakh to ₹7 lakh over two years.
R&D investment at 4.2% of revenue, up 50 bps YoY, focused on biosimilars and ADCs.
Zuventus represents ~40% of total MR count; restructuring caused higher attrition but recovery seen in April.
Organic patient volume grew 9.3% in Q4 FY26, driven by network expansion and demand.
Revenue per patient improved ~5% YoY in Q4, driven by specialty and wellness mix.
Digital channels now contribute 25% of revenue, up from 0% three years ago.
Improved from 20:1 to 24:1, targeting 35:1 over three years.
Management expects revenue growth in the low-to-mid teen percentage range for FY27, assuming stable macro conditions.
Management guidance revenueManagement committed to expanding EBITDA margins by 75-100 basis points in FY27, driven by operating leverage and productivity gains.
Management guidance marginsCapital expenditure for FY27 is expected to be in the range of ₹400-425 crore.
Management guidance capexAim for steady growth of the semaglutide brand Pista in FY27, leveraging competitive pricing and clinical differentiation.
Management guidance growthDriven by 8-9% patient volume growth and ~5% realization improvement, with potential price increases.
Management guidance revenueSupported by operating leverage, productivity gains, and core diagnostics reaching 20%+ margin.
Management guidance marginsManagement expects EBITDA margin expansion of 125-150 bps in the coming fiscal year.
Management guidance marginsExpand asset-light network and upgrade centers to include basic radiology, targeting center-to-lab ratio of 35:1.
Management guidance expansionRising solvent prices, insurance, and freight costs due to Middle East conflict could pressure margins if not passed through.
medium · analyst_questionDespite management's confidence, the acute nature of Zuventus portfolio means sales recovery may take longer than expected.
medium · analyst_questionMultiple generic entrants in the GLP-1 market could limit Pista's market share and revenue contribution.
high · management_commentaryInternational business faces currency headwinds; guidance assumes average USD/INR of 92, but actual rates may vary.
low · data_observationGrowth in tier-1 cities like Mumbai is around 11-14%, potentially constrained by high competition from organized and unorganized players.
medium · analyst_questionWhile current acquisitions are on track, future deals may face quality and integration challenges, as management noted many assets do not meet their standards.
medium · management_commentaryManagement indicated no price hike planned currently, but realization growth partly relies on future price increases, which may not materialize if competitive pressures persist.
low · data_observationWe crossed a major milestone this year, surpassing $1 billion in revenue and having a growth of 16.6% year-on-year increase, exceeding the guidance row that we had given to you.
Our adjusted PAT grew more than 40%, I repeat, our adjusted PAT grew more than 40%.
We are not looking at a price increase, but as the things progresses during the year, if there is a need for us to do it, we would not hesitate to do it.
We believe a sustainable EBITDA at this point over the next three years of 27 to 28% makes sense for us and if we are able to generate more operating leverage we would like to invest it back in the business.
